A retrospective cohort study of patients with COVID-19 presenting with hyperinflammation (ferritin > 1000 ng/mL and/or d-dimers > 1.5 μg/mL, plus IL-6 < 40 mg/mL) and ARDS (PaO2/FiO2 < 300) showed that the mortality of patients treated with anakinra was similar to patients administered with tocilizumab. This evidence concerns the gene IL6 and COVID-19.